小海购入的价格应该在10刀，这么多年了还跌30%，如果三期数据不错的话也不会在这个时候定增，应该是利空。

接近7刀，定向增发103万股，融资700万刀（美刀也或加刀），机构投资者是谁，股价反应市场认可，港海未发公告，或是第三方机构，港海手软了，为什么不加仓。On March 15, 2021, Aridis Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to offer, issue and sell to the Purchasers, in a registered direct offering, an aggregate of 1,037,405 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”) for aggregate gross proceeds to the Company of approximately $7.0 million, before deducting estimated offering expenses payable by the Company.
 
The Shares are being offered by the Company pursuant to an effective shelf registration statement on Form S-3, which was originally filed with the Securities and Exchange Commission on September 3, 2019, and was declared effective on September 5, 2019 (File No. 333-233601) (the “Registration Statement”).
 
In addition, the Company is issuing 124,789 shares of unregistered Common Stock to the investors in the Company’s October 2020 offering pursuant to Section 4(v) of the Securities Purchase Agreement dated October 13, 2020 between the Company and the purchasers identified on the signature pages thereto, as amended on February 25, 2021 (the “Anti-Dilution Shares”).
 
The closing of the offering described above is subject to satisfaction of specified customary closing conditions.
 
The foregoing summary of the offering, the securities to be issued in connection therewith and the Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the definitive transaction documents. A copy of the form of Purchase Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.